The survey found that almost nine in 10 pharmacists are concerned about the supply of medicines now that Brexit is underway.
News
Could ‘tailor-made’ vaccines halve bacterial disease rates?
The findings coincide with growing alarm at the threat of antimicrobial resistance (AMR) to common medicines, after last year a UN report revealed that if left unchecked, AMR could cause as many as 10 million deaths per year by 2050.
Givlaari, Nubeqa among Jan CHMP decisions
The committee recommended fifteen medicines for approval at its first meeting of 2020, as well as six extensions of current indications.
60% of UK unis expect Brexit to affect pharma industry relationships
The UK is expected to officially leave the European Union at 11PM tonight, January 31st.
Nubeqa success in Phase III prostate cancer study
“A positive trend in overall survival” had been seen in a trial, with an interim analysis demonstrating a 29% reduction in the risk of death for Nubeqa.
LEO issues Picato recall
Last September, the EMA’s Pharmacovigilance Risk Assessment Committee announced a review of data on skin cancer in patients using the drug.
GSK hit with EU Court ruling over ‘pay-for-delay’ drug case
The ruling harks back to the CMA’s 2016 case that found GlaxoSmithKline had agreed to make payments totalling over £50 million to other generic suppliers of paroxetine.
Peanut allergy vaccine shows promise
There are currently no approved immunotherapies for the treatment of peanut allergies.
New drug candidate created by AI in ‘world first’
The drug, DSP-1181, was created through joint research by both the companies and Centaur Chemist’s AI platform.
J&J launches ‘multi-pronged’ coronavirus response
Using its AdVac and PER.C6 technologies, the company wants to rapidly upscale production of the optimal vaccine candidate.
NHS to tackle climate “health emergency” with new campaign
The campaign, dubbed “For a Greener NHS”, will address both the causes of climate change and air pollution.
New treatment ‘made from sugar’ could help fight viral outbreaks
The team has “successfully engineered a new molecule, which is a modified sugar that shows broad-spectrum antiviral properties.”
EMA validates Kite’s CAR-T filing
In December last year the company also filed the CAR-T therapy with the FDA.
Industry leading companies are entering their best and brightest in CROY 2020
The 2020 competition has already seen a large number of top industry companies being represented as we approach the final month of entries.
European Commission expands use for Janssen’s Erleada
The extension is based on data from the Phase III TITAN study, which assessed the addition of the drug to androgen deprivation therapy in a broad range of patients with metastatic hormone-sensitive prostate cancer.
